Israel Supreme Court Backs Sun Pharma For Taro Deal But Litigation May Not Be Over
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Sun Pharma's prolonged three-year battle to wrest control of Israeli generic drug maker Taro looks headed for a conclusion as the Israeli Supreme Court - after several months - allowed the Indian company to pursue purchase of outstanding shares, thereby dealing a blow to Taro's efforts to scuttle the takeover bid
You may also be interested in...
Sun Finally Gains Control Of Taro As Founders Relent; Charts Out Aggressive Investment And Growth Plans
HYDERABAD - Bound by Israel's Supreme Court verdict earlier this month, drug firm Taro's founders - the Levitt and Moros families - have finally conceded management control of the 60-year old company that specializes in dermatology products to Sun Pharma - India's largest company by market capitalization
Sun Finally Gains Control Of Taro As Founders Relent; Charts Out Aggressive Investment And Growth Plans
HYDERABAD - Bound by Israel's Supreme Court verdict earlier this month, drug firm Taro's founders - the Levitt and Moros families - have finally conceded management control of the 60-year old company that specializes in dermatology products to Sun Pharma - India's largest company by market capitalization
Once More Taro Takes Sun Pharma To Court; Alleges Failure To Disclose Information About U.S. FDA Action Against Caraco
MUMBAI - India's Sun Pharmaceutical has more court battles to deal with as its takeover target Taro Pharmaceutical of Israel has filed one more case in a New York court alleging that its bidder failed to disclose "material information to Taro shareholders and unlawful use of confidential information.